Abvc Biopharma (ABVC) Deferred Taxes (2018 - 2023)

Abvc Biopharma (ABVC) has reported Deferred Taxes for 6 consecutive years, with $151387.0 the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Deferred Taxes fell 83.11% year-over-year to $151387.0; the trailing twelve-month figure through Dec 2023 stood at $1.1 million (up 23.6% YoY), and the FY2023 full-year result was $115668.0, down 86.62% from the prior year.
• Deferred Taxes grew to $151387.0 in Q4 2023 per ABVC's latest filing, from -$117414.0 in the prior quarter.
• Across five years, Deferred Taxes topped out at $896049.0 in Q4 2022 and bottomed at -$117414.0 in Q3 2023.
• Historically, Deferred Taxes has averaged $83475.4 across 5 years, with a median of -$40568.0 in 2020.
• The sharpest annual moves came in 2020 and 2021: Deferred Taxes slumped 207.99% in 2020, then jumped 756.76% in 2021.
• Over 5 years, Deferred Taxes stood at -$28054.0 in 2019, then plunged by 207.99% to -$86404.0 in 2020, then surged by 756.76% to $567468.0 in 2021, then soared by 57.9% to $896049.0 in 2022, then plunged by 83.11% to $151387.0 in 2023.
• According to Business Quant data, Deferred Taxes over the past three periods registered $151387.0, -$117414.0, and $896049.0 for Q4 2023, Q3 2023, and Q4 2022 respectively.